Mucosal Resurfacing in the Management of Type II Diabetes

Manoel Galvão Neto; Thomas R. McCarty; Josemberg Marins Campos; Luiz Gustavo de Quadros

doi:10.1007/978-3-031-70004-0_37

Mucosal Resurfacing in the Management of Type II Diabetes

Manoel Galvão Neto, Thomas R. McCarty, Josemberg Marins Campos, Luiz Gustavo de Quadros

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Given the shared pathophysiology of obesity and associated comorbid conditions, the number of individuals with concomitant type II diabetes mellitus (T2DM) has also increased. Obesity and T2DM have grown to epidemic proportions among industrialized countries with a prevalence that has more than doubled in the last 25 years. Worldwide, there are around 380 million people living with T2DM with an estimated 3.8 million deaths that occur annually due to diabetes or poor glucose control. In this setting, the duodenum has been recognized more and more as a metabolic signaling center with role in the regulation of insulin resistance. Recent advances in endoluminal technology using endoscopic bariatric and metabolic therapies (EBMTs) are promising. Thus, the application of new EBMT technologies has found a role in the concomitant treatment of obesity and T2DM. The duodenal mucosal resurfacing (DMR) procedure involves hydrothermal ablation of the duodenal mucosa and mucosal healing in effort to improve obesity as well as glucose homeostasis.

Original language	English (US)
Title of host publication	Bariatric Endoscopy
Publisher	Springer Nature
Pages	411-416
Number of pages	6
ISBN (Electronic)	9783031700040
ISBN (Print)	9783031700033
DOIs	https://doi.org/10.1007/978-3-031-70004-0_37
State	Published - Jan 1 2025

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-3-031-70004-0_37

Cite this

@inbook{6475f95e8a2d494eaf4a798d6ab4566a,

title = "Mucosal Resurfacing in the Management of Type II Diabetes",

abstract = "Given the shared pathophysiology of obesity and associated comorbid conditions, the number of individuals with concomitant type II diabetes mellitus (T2DM) has also increased. Obesity and T2DM have grown to epidemic proportions among industrialized countries with a prevalence that has more than doubled in the last 25 years. Worldwide, there are around 380 million people living with T2DM with an estimated 3.8 million deaths that occur annually due to diabetes or poor glucose control. In this setting, the duodenum has been recognized more and more as a metabolic signaling center with role in the regulation of insulin resistance. Recent advances in endoluminal technology using endoscopic bariatric and metabolic therapies (EBMTs) are promising. Thus, the application of new EBMT technologies has found a role in the concomitant treatment of obesity and T2DM. The duodenal mucosal resurfacing (DMR) procedure involves hydrothermal ablation of the duodenal mucosa and mucosal healing in effort to improve obesity as well as glucose homeostasis.",

author = "Neto, {Manoel Galv{\~a}o} and McCarty, {Thomas R.} and Campos, {Josemberg Marins} and {de Quadros}, {Luiz Gustavo}",

note = "Publisher Copyright: {\textcopyright} The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2013, 2024.",

year = "2025",

month = jan,

day = "1",

doi = "10.1007/978-3-031-70004-0_37",

language = "English (US)",

isbn = "9783031700033",

pages = "411--416",

booktitle = "Bariatric Endoscopy",

publisher = "Springer Nature",

address = "United States",

}

TY - CHAP

T1 - Mucosal Resurfacing in the Management of Type II Diabetes

AU - Neto, Manoel Galvão

AU - McCarty, Thomas R.

AU - Campos, Josemberg Marins

AU - de Quadros, Luiz Gustavo

N1 - Publisher Copyright: © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2013, 2024.

PY - 2025/1/1

Y1 - 2025/1/1

N2 - Given the shared pathophysiology of obesity and associated comorbid conditions, the number of individuals with concomitant type II diabetes mellitus (T2DM) has also increased. Obesity and T2DM have grown to epidemic proportions among industrialized countries with a prevalence that has more than doubled in the last 25 years. Worldwide, there are around 380 million people living with T2DM with an estimated 3.8 million deaths that occur annually due to diabetes or poor glucose control. In this setting, the duodenum has been recognized more and more as a metabolic signaling center with role in the regulation of insulin resistance. Recent advances in endoluminal technology using endoscopic bariatric and metabolic therapies (EBMTs) are promising. Thus, the application of new EBMT technologies has found a role in the concomitant treatment of obesity and T2DM. The duodenal mucosal resurfacing (DMR) procedure involves hydrothermal ablation of the duodenal mucosa and mucosal healing in effort to improve obesity as well as glucose homeostasis.

AB - Given the shared pathophysiology of obesity and associated comorbid conditions, the number of individuals with concomitant type II diabetes mellitus (T2DM) has also increased. Obesity and T2DM have grown to epidemic proportions among industrialized countries with a prevalence that has more than doubled in the last 25 years. Worldwide, there are around 380 million people living with T2DM with an estimated 3.8 million deaths that occur annually due to diabetes or poor glucose control. In this setting, the duodenum has been recognized more and more as a metabolic signaling center with role in the regulation of insulin resistance. Recent advances in endoluminal technology using endoscopic bariatric and metabolic therapies (EBMTs) are promising. Thus, the application of new EBMT technologies has found a role in the concomitant treatment of obesity and T2DM. The duodenal mucosal resurfacing (DMR) procedure involves hydrothermal ablation of the duodenal mucosa and mucosal healing in effort to improve obesity as well as glucose homeostasis.

UR - http://www.scopus.com/inward/record.url?scp=105005236793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=105005236793&partnerID=8YFLogxK

U2 - 10.1007/978-3-031-70004-0_37

DO - 10.1007/978-3-031-70004-0_37

M3 - Chapter

AN - SCOPUS:105005236793

SN - 9783031700033

SP - 411

EP - 416

BT - Bariatric Endoscopy

PB - Springer Nature

ER -

Mucosal Resurfacing in the Management of Type II Diabetes

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this